One small biotech holds the key to a revolution in treating Alzheimer's disease. Jeff Bezos, Goldman Sachs & Big Pharma giants have invested billions into this unknown biotech. Our research proves that anyone who gets in today could see gains as high as 113,000%!

Maydan Rothblum Biography and Net Worth

CFO of The Glimpse Group

Mr. Maydan Rothblum is a Managing Director at Sigma Capital Partners LLC. Prior to joining Sigma Capital Partners, Mr. Rothblum held Associate level positions at Apax Partners, Zacks Investment Research, and Booz, Allen & Hamilton where he gained experience in private equity investing, equity research and business consulting, both nationally and internationally. Mr. Rothblum had earlier experience at Sunrise Projects, managing private placement engagements for Israeli high tech companies. In addition, he served as an Engineer in the Israeli Defense Force (IDF).

Mr. Rothblum holds an MBA in Finance and International Business from Columbia Business School and a BS in Industrial Engineering and Management from the Technion Israel Institute of Technology.

How old is Maydan Rothblum?: Mr. Rothblum is currently 51 years old. There are 4 older executives and no younger executives at The Glimpse Group. The oldest executive at The Glimpse Group is Mr. Jeffrey Meisner, Chief Revenue Officer & Director, who is 62 years old. Learn More on Maydan Rothblum's age.
How do I contact Maydan Rothblum?: The corporate mailing address for Mr. Rothblum and other The Glimpse Group executives is , , . The Glimpse Group can also be reached via phone at 917-292-2685 and via email at [email protected]. Learn More on Maydan Rothblum's contact information.
Has Maydan Rothblum been buying or selling shares of The Glimpse Group?: Maydan Rothblum has not been actively trading shares of The Glimpse Group within the last three months. Most recently, on Tuesday, March 8th, Maydan Rothblum bought 2,100 shares of The Glimpse Group stock. The stock was acquired at an average cost of $5.12 per share, with a total value of $10,752.00. Learn More on Maydan Rothblum's trading history.
Who are The Glimpse Group's active insiders?: The Glimpse Group's insider roster includes Lemuel Amen (Director), Lyron Bentovim (CEO), Maydan Rothblum (CFO), Alexander Ruckdaeschel (Director), and David Smith (Insider). Learn More on The Glimpse Group's active insiders.

Maydan Rothblum Insider Trading History at The Glimpse Group

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
3/8/2022	Buy	2,100	$5.12	$10,752.00
10/1/2021	Buy	750	$7.27	$5,452.50

Maydan Rothblum Buying and Selling Activity at The Glimpse Group

The Glimpse Group Company Overview

The Glimpse Group, Inc., a virtual reality (VR) and augmented reality (AR) platform company, provides enterprise-focused software, services, and solutions in the United States. It offers QReal, a software that creates and distributes photorealistic 3D interactive digital models and experiences in AR; Immersive Health Group, a VR/AR platform for evidence-based and outcome driven healthcare solutions; and Foretell Reality, a social VR platform for behavioral health, support groups, collaboration, and soft skills training. The company also provides Glimpse Turkey for developing and creating 3D models for QReal; XR Terra that provides immersive technologies for teaching courses and training; Sector 5 Digital for corporate immersive experiences and events; PulpoAR, an AR try-on technology that targets the beauty and cosmetics industry; and Brightline Interactive, which offers immersive and interactive experiences, training scenarios, and simulations for government and commercial customers. The company was incorporated in 2016 and is headquartered in New York, New York.

Today's Range

Now: $1.11

$1.10

$1.19

50 Day Range

MA: $1.28

$1.08

$1.60

2 Week Range

Now: $1.11

$0.86

$6.00

Volume

13,834 shs

Average Volume

50,475 shs

Market Capitalization

$18.65 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

2.22

The World's First "$20 Trillion Drug?"

From Behind the Markets | Ad

Get the name of the stock here >>>